854 related articles for article (PubMed ID: 12661846)
1. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Danckwerts MP; Ebrahim S; Pillay V
Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
[TBL] [Abstract][Full Text] [Related]
2. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
Dekker TG; Lötter AP
Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
[No Abstract] [Full Text] [Related]
3. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.
Bhutani H; Singh S; Jindal KC; Chakraborti AK
J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767
[TBL] [Abstract][Full Text] [Related]
5. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
[TBL] [Abstract][Full Text] [Related]
6. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
[TBL] [Abstract][Full Text] [Related]
7. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
8. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
Shah AR; Agarwal SK; Shah KV
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
10. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
11. [Antitubercular chemotherapy].
Jouveshomme S; Dautzenberg B
Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
[TBL] [Abstract][Full Text] [Related]
12. Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
Harries AD; Gausi F; Salaniponi FM
Int J Tuberc Lung Dis; 2004 Jun; 8(6):724-9. PubMed ID: 15182142
[TBL] [Abstract][Full Text] [Related]
13. [Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms].
Sokolova GB; Koriakin VA; Khalbaeva IV; Elistratova NA; Ziia AV
Probl Tuberk; 1993; (5):21-3. PubMed ID: 8295879
[TBL] [Abstract][Full Text] [Related]
14. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Ahn HC; Lee YC
Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
[TBL] [Abstract][Full Text] [Related]
15. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
Kononets AS
Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
[TBL] [Abstract][Full Text] [Related]
16. Design and optimization of a child-friendly dispersible tablet containing isoniazid, pyrazinamide, and rifampicin for treating tuberculosis in pediatrics.
Suárez-González J; Santoveña-Estévez A; Soriano M; Fariña JB
Drug Dev Ind Pharm; 2020 Feb; 46(2):309-317. PubMed ID: 31944867
[No Abstract] [Full Text] [Related]
17. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
[TBL] [Abstract][Full Text] [Related]
19. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
20. The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules.
Ellard GA
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S343-6; discussion S351-2. PubMed ID: 10593715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
